Skip to content
Disclosery

Decheng Capital LLC

Follow

13F filer, CIK 2010850, MENLO PARK, CA

Decheng Capital LLC reported $661,316,235 across 14 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-13. Its ten largest share positions make up 98.23% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-26-060145

Period
2026-03-31
Reported value
$661M
Holdings
14
Top 10 weight
98.23%
New
0
Sold out
5

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RVMDreduced-106,500-$10.4M
NAMSreduced-267,000-$8.55M
CRNXexited-92,700-$4.32M
UPBreduced-418,210-$3.76M
KRYSreduced-10,000-$2.58M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001104659-26-060145, largest first. % of portfolio is the value over $661,316,235, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 5,478,810 shares; 2024Q4: 6,371,669 shares; 2025Q1: 6,371,669 shares; 2025Q2: 6,371,669 shares; 2025Q3: 6,371,669 shares; 2025Q4: 6,371,669 shares; 2026Q1: 6,371,669 shares 6,371,669$431M65.21%0Timeline
NUVBNUVATION BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 25,954,439 shares; 2024Q4: 25,954,439 shares; 2025Q1: 25,954,439 shares; 2025Q2: 25,954,439 shares; 2025Q3: 25,954,439 shares; 2025Q4: 25,954,439 shares; 2026Q1: 25,954,439 shares 25,954,439$111M16.84%0Timeline
UPBUPSTREAM BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 3,285,293 shares; 2025Q1: 3,285,293 shares; 2025Q2: 3,285,293 shares; 2025Q3: 3,285,293 shares; 2025Q4: 3,143,078 shares; 2026Q1: 2,724,868 shares 2,724,868$24.5M3.71%-418,210Timeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,266,667 shares; 2025Q1: 4,041,736 shares; 2025Q2: 4,041,736 shares; 2025Q3: 4,041,736 shares; 2025Q4: 4,041,736 shares; 2026Q1: 4,041,736 shares 4,041,736$15.2M2.29%0Timeline
AARDAARDVARK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 3,917,299 shares; 2025Q2: 3,917,299 shares; 2025Q3: 3,917,299 shares; 2025Q4: 3,917,299 shares; 2026Q1: 3,917,299 shares 3,917,299$14.8M2.23%0Timeline
LYELL IMMUNOPHARMA INCLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 11,909,341 shares; 2025Q1: 11,909,341 shares; 2025Q2: 595,466 shares; 2025Q3: 595,466 shares; 2025Q4: 692,050 shares; 2026Q1: 692,050 shares 692,050$13.9M2.1%0
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 590,000 shares; 2024Q4: 770,000 shares; 2025Q1: 770,000 shares; 2025Q2: 770,000 shares; 2025Q3: 657,051 shares; 2025Q4: 592,057 shares; 2026Q1: 325,057 shares 325,057$10.4M1.57%-267,000Timeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 869,790 shares; 2024Q4: 808,789 shares; 2025Q1: 808,789 shares; 2025Q2: 160,000 shares; 2025Q3: 547,609 shares; 2025Q4: 541,559 shares; 2026Q1: 477,819 shares 477,819$10.3M1.56%-63,740Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,000 shares; 2024Q4: 226,000 shares; 2025Q1: 226,000 shares; 2025Q2: 226,000 shares; 2025Q3: 210,000 shares; 2025Q4: 200,000 shares; 2026Q1: 93,500 shares 93,500$9.09M1.37%-106,500Timeline
EQEQUILLIUM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 4,447,308 shares; 2024Q4: 4,447,308 shares; 2025Q1: 4,447,308 shares; 2025Q2: 4,447,308 shares; 2025Q3: 4,447,308 shares; 2025Q4: 4,447,308 shares; 2026Q1: 4,447,308 shares 4,447,308$8.89M1.34%0Timeline
BYSIBEYONDSPRING INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 4,958,143 shares; 2024Q4: 4,882,651 shares; 2025Q1: 4,882,651 shares; 2025Q2: 4,531,481 shares; 2025Q3: 4,286,104 shares; 2025Q4: 3,800,702 shares; 2026Q1: 3,800,702 shares 3,800,702$6.23M0.94%0Timeline
ZNTLZENTALIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 3,108,095 shares; 2024Q4: 2,338,095 shares; 2025Q1: 2,019,762 shares; 2025Q2: 1,323,327 shares; 2025Q3: 1,323,327 shares; 2025Q4: 1,323,327 shares; 2026Q1: 1,323,327 shares 1,323,327$3.1M0.47%0Timeline
KRYSKRYSTAL BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 71,772 shares; 2024Q4: 76,772 shares; 2025Q1: 65,000 shares; 2025Q2: 66,000 shares; 2025Q3: 32,300 shares; 2025Q4: 17,300 shares; 2026Q1: 7,300 shares 7,300$1.89M0.29%-10,000Timeline
PYXSPYXIS ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 326,810 shares; 2024Q4: 326,810 shares; 2025Q1: 326,810 shares; 2025Q2: 326,810 shares; 2025Q3: 326,810 shares; 2025Q4: 326,810 shares; 2026Q1: 326,810 shares 326,810$477K0.07%0Timeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CRNXCRINETICS PHARMACEUTICALS IN92,700$4.32Mshares
AURAAURA BIOSCIENCES INC360,483$1.96Mshares
FDMT4D MOLECULAR THERAPEUTICS IN44,311$332Kshares
NUVATION BIO INCNUVATION BIO INC646,057$213Kshares
RZLTREZOLUTE INC59,900$141Kshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-060145 base2026-05-13acceptance time not in the bulk data set